Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

To advance the use of circulating tumor DNA (ctDNA) applications, their broad clinical validity must be tested in different treatment settings, including targeted therapies. Using the prespecified longitudinal systematic collection of plasma samples in the phase 1/2a LYM1002 trial (registered on www...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruscaggin, Alessio, di Bergamo, Lodovico Terzi, Spina, Valeria, Hodkinson, Brendan, Forestieri, Gabriela, Bonfiglio, Ferdinando, Condoluci, Adalgisa, Wu, Wei, Pirosa, Maria C., Faderl, Martin R., Koch, Ricardo, Schaffer, Michael, Alvarez, John D., Fourneau, Nele, Gerber, Bernhard, Stussi, Georg, Zucca, Emanuele, Balasubramanian, Sriram, Rossi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759132/
https://www.ncbi.nlm.nih.gov/pubmed/34500472
http://dx.doi.org/10.1182/bloodadvances.2021004528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759132/
https://www.ncbi.nlm.nih.gov/pubmed/34500472
http://dx.doi.org/10.1182/bloodadvances.2021004528

Ejemplares similares